Crescendo Bioscience has appointed Elena Hitraya as chief medical officer, effective October 1. In this role, she will lead efforts to provide professional education initiatives, to expand market access for Vectra DA, and to develop the company's pipeline of autoimmune products. During the past 11 years, Hitraya has held leadership positions at Genentech, most recently as group medical director for rheumatology/immunology for the Genentech/Roche group. Prior to Genentech, she was regional director of medical affairs for immunology at Cenotocor, a divison of Johnson & Johnson.
Cynvenio Biosystems has hired Paul Song as its chief medical officer to oversee the firm's translational and clinical research programs. He will be responsible for all clinical utility activities, including trial definition, institutional partner selection, and patient stratification. He also will coordinate global activities with international partners, in particular those in Europe and China. Song is on the faculty at Cedars Sinai Medical Center and is CMO at AT-Gen. He is also a senior adviser at Berg Health.
Agena Bioscience has appointed Bob Wang as vice president and general manager for greater China. He was most recently the marketing director for Qiagen, where he was responsible for leading the development of its molecular diagnostics and life science commercial strategies. Prior to this, Wang held senior positions in business development, marketing, sales, and regulatory affairs at Hologic, Life Technologies, Applied Biosystems, and the Chinese Human Genome Center.
GenomOncology has appointed Benjamin Salisbury as vice president of new products and marketing. He will be responsible for the company's corporate marketing and for bringing to market new products that build upon the company's precision medicine technology. Salisbury joins the company from Knome, where he guided the transition of the company's research-focused, internal-use software for next-generation sequencing analysis to a product that supports clinical laboratory operations. He has also held several management and scientific positions at Transgenomic, PGxHealth, and Genaissance Pharamaceuticals. As a scientist, Salisbury's expertise includes molecular diagnostics, pharmacogenomics, population genetics, statistical genetics, and algorithm development. He has authored over 30 peer-reviewed publications in these and other fields.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.